News & Updates

The interaction between genetic and environmental factors, specifically obesity and hyperglycaemia, contributes to an increased risk of renal cell cancer (RCC), suggests a study.

Patients with locally advanced rectal cancer who achieve complete response (CR) following sequential short-course radiation therapy (SCRT) and chemotherapy appear to benefit from nonoperative management (NOM) with a watch-and-wait strategy, which presents evidence for good anorectal functions, results of a study have shown.

Olaparib demonstrates clinical activity across patients with platinum-sensitive relapsed ovarian cancer and known BRCA mutation and homologous recombination deficiency (HRD), as shown in the phase II LIGHT study.

Trastuzumab deruxtecan led to greater survival outcomes than chemotherapy treatment of physician’s choice (TPC)* in patients with HER2-low** advanced breast cancer, according to results of a phase III trial presented at ASCO 2022.

A prostate specific antigen (PSA)-based screening is effective in significantly lowering the risk of death from prostate cancer (PC), reports a study. However, nonattendance, initiation after age 60 years, and discontinuation at age 70 years appear to increase such risk.

Alterations in normal gut mycobiota profile, particularly the enrichment of the pathogenic Aspergillus rambellii, appear to aggravate the risk of colorectal cancer (CRC), according to a recent study.

Panitumumab plus modified FOLFOX6 (mFOLFOX6; fluorouracil, leucovorin, and oxaliplatin) as first-line therapy significantly improves overall survival (OS) vs bevacizumab plus mFOLFOX6 in patients with left-sided RAS wild-type (wt) metastatic colorectal cancer (mCRC), results of the Japanese PARADIGM trial have shown.